To propose heterologous vaccination as a public health strategy, supported by evidence from clinical trials, to enhance hybrid immunity against SARS-CoV-2.
Key Findings:
Hybrid immunity induces more potent and durable immune responses compared to single-modality approaches, as evidenced by clinical data.
Heterologous vaccination enhances the breadth of neutralizing antibodies and strengthens cross-protection, supported by trial results.
Natural infection combined with heterologous vaccination mimics the benefits of natural infection without associated risks, as shown in studies.
Interpretation:
Heterologous vaccination can effectively simulate and optimize hybrid immunity, providing a robust defense against evolving SARS-CoV-2 variants, as indicated by recent findings.
Limitations:
Real-world efficacy of second-generation vaccines depends on individual immune history, which can vary widely.
Potential risks associated with natural infection remain, including severe disease and long-term health effects.
Conclusion:
Heterologous vaccination represents a strategic tool to build a resilient population-wide immune barrier against SARS-CoV-2.
Protection against spread appeared strongest within 6 months of vaccination, while exposed vaccinated contacts showed no measurable reduction in infection risk.
